Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2021 Oct 31;36(2):e91–e93. doi: 10.1111/jdv.17736

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 European Academy of Dermatology and Venereology

This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.

PMC Copyright notice

Clinical presentation and histology before (a–e) and after (f–j) the vaccine. (a) Purple patch on the occipital area, (b) H&E ×20: Lymphoid infiltration of the dermis with prominent folliculotropism, (c) CD3 ×40: CD3 expression, (d) CD4 ×20: CD4 expression, (e) CD30 ×20: Sparse CD30 positivity, (f) Lichenoid induration and small nodules on the periphery of the patch, (g) H&E ×20: dense, diffuse, full thickness lymphoid infiltration of the dermis, (h) H&E ×400: increased numbers of large neoplastic T lymphocytes among the lymphocytic population, (i) CD3 X 20: CD3 expression, (j) CD30 ×40: extensive CD30 positivity mainly in the large anaplastic T lymphocytes (transformation to peripheral CD30+ T‐cell lymphoma).